View Author
stent patient spirit trial spirit ii follow-up 3 years lesion analysis 3- year outcomes target death stent thrombosis 3- year follow-up stent system event artery lesions reduction study outcome artery thrombosis xience randomized treatment paclitaxel-eluting ef ficacy iii trials jacc everolimu vessel finite signi spirit iii point research paclitaxel-eluting stents eluting iii trials ficacy everolimus-eluting target vessel failure revascularization sirolimus-eluting failure system intervention table evaluation ischemia-driven group ischemia-driven tlr infarction caixeta 1 year safety sirolimus-eluting stents ficant subgroup drug-eluting signi ficant reduction value abbott result end points diabetes xience v december patients randomized artery disease figure bare-metal stents stone signi ficantly investigator month consortium 0.59 patient-level hazard everolimus-eluting stent
1 Most Recent Publications
|
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: A pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE v Everolimus Eluting Coronary Stent System in the Treatment of Patients with de Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE v Everolimus Eluting Coronary Stent System [EECSS]
(Article)
Caixeta, A. Lansky, A.J. Sood, P. Su, X. Jonnavithula, L. Sudhir, K. Stone, G.W. Serruys, P.W.J.C. Hermiller, J.B. Ruygrok, P.N. Onuma, Y. Gordon, P. Yaqub, M. Miquel-Hébert, K. Veldhof, S. |
2010-12-01
|